641 results on '"Mourah, Samia"'
Search Results
2. Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1
3. Effect of ultrasound-mediated blood-spinal cord barrier opening on survival and motor function in females in an amyotrophic lateral sclerosis mouse model
4. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
5. Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study
6. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
7. Graft-versus-lymphoma effect in skin after allogeneic hematopoietic stem cell transplantation for Sézary syndrome
8. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
9. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
10. Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases.
11. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
12. Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription
13. Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK
14. Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach
15. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
16. Metastatic perirectal PEComa treated by checkpoint inhibitor immunotherapy and multimodal treatment: case report and review of the literature.
17. The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review
18. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
19. Impact of blood tumour clone frequency on time to next treatment in mycosis fungoides
20. Targeting TGF-beta activation in cutaneous T-cell lymphomas
21. Sezary syndrome revealed by PD‐L1 blockade for tumor stage mycosis fungoides
22. Erratum to ‘Molecular profiling of anal Paget’s disease and underlying anal adenocarcinoma highlights their common origin’ [EJC Skin Cancer 1 (2023) 100002]
23. CD30-positive anaplastic large-cell lymphoma associated with mycosis fungoides after treatment with dupilumab
24. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
25. Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas
26. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
27. Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models
28. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
29. Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data
30. Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin
31. Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)
32. Primary cutaneous follicle center lymphoma with secondary systemic evolution
33. Severe relapses of cutaneous T‐cell lymphoma after treatment of chronic graft‐versus‐host disease with ruxolitinib
34. Tre-P-08 - Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series
35. Epi-O-07 - Granulomatous slack skin: clinical retrospective study of 8 cases of the Cutaneous Lymphoma French Study Group
36. Bio-O2-03 - Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker
37. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
38. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
39. Ibrutinib brain distribution: a preclinical study
40. TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
41. Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease
42. Recurrent PAK2 rearrangements in poroma with folliculo‐sebaceous differentiation
43. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov
44. Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients
45. Microsecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases.
46. Supplementary Figure from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
47. Supplementary Data from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
48. Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
49. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients
50. Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.